Jennison Associates
CRNX

Jennison Associates’s Crinetics Pharmaceuticals CRNX Stock Holding History

Jennison Associates’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.06M Sell
161,861
-742,811
-82% -$27.6M ﹤0.01% 421
2026
Q1 		$32.9M Sell
904,672
-376,929
-29% -$16.8M 0.02% 273
2025
Q4 		$59.7M Sell
1,281,601
-763,133
-37% -$34M 0.04% 182
2025
Q3 		$85.2M Buy
2,044,734
+57,616
+3% +$1.84M 0.05% 149
2025
Q2 		$57.1M Sell
1,987,118
-132,649
-6% -$4.1M 0.03% 201
2025
Q1 		$71.1M Sell
2,119,767
-588,584
-22% -$22M 0.05% 161
2024
Q4 		$138M Sell
2,708,351
-85,263
-3% -$4.77M 0.08% 106
2024
Q3 		$143M Buy
2,793,614
+13,470
+0.5% +$695K 0.09% 94
2024
Q2 		$125M Sell
2,780,144
-37,710
-1% -$1.74M 0.08% 98
2024
Q1 		$132M Buy
2,817,854
+270,171
+11% +$10.6M 0.09% 94
2023
Q4 		$90.6M Buy
2,547,683
+1,113,992
+78% +$34.2M 0.07% 124
2023
Q3 		$42.6M Buy
1,433,691
+972,194
+211% +$20M 0.04% 196
2023
Q2 		$8.32M Buy
+461,497
New +$9.2M 0.01% 391

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates's CRNX Position: Q2 2026 in Review

Jennison Associates reduced its Crinetics Pharmaceuticals (CRNX) stake by 82% in Q2 2026, selling an estimated $27.6M and leaving 161,861 shares worth $6.06M. The position accounts for ﹤0.01% of the portfolio, ranked #421.

Jennison Associates first reported a position in CRNX in Q2 2023 and has held it in 13 quarters since. The position peaked at $143M in Q3 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Jennison Associates held 161,861 shares of Crinetics Pharmaceuticals worth $6.06M as of Q2 2026.
  • Jennison Associates sold 742,811 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $27.6M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Jennison Associates's portfolio in Q2 2026, its #421 holding.
  • Jennison Associates first reported a position in Crinetics Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Jennison Associates's Crinetics Pharmaceuticals position peaked at $143M in Q3 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.